ZEB2 and ovarian serous adenocarcinoma: Li et al. have shown that the expression of ZEB2 and vimentin is increased, while E-cadherin expression is decreased in ascitic tumor cells compared to primary high-grade serous ovarian cancers; increased ZEB2 expression in primary and peritoneal metastatic high-grade serous ovarian cancer is associated with inferior overall survival and progression-free survival of affected patients.